Stay updated on Periop mFOLFOX + Pembrolizumab in GEJ & Stomach Clinical Trial
Sign up to get notified when there's something new on the Periop mFOLFOX + Pembrolizumab in GEJ & Stomach Clinical Trial page.

Latest updates to the Periop mFOLFOX + Pembrolizumab in GEJ & Stomach Clinical Trial page
- CheckyesterdayChange DetectedAdded a government funding lapse notice and updated the site to revision v3.4.1 (with v3.4.0 removed). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check8 days agoChange DetectedGlossary visibility has been enabled on the page. The update history metadata now shows 'Last Update Submitted that Met QC Criteria' and the revision tag has been updated to v3.4.0.SummaryDifference0.2%

- Check16 days agoChange DetectedAddition: Revision: v3.3.4 and deletion: Revision: v3.3.3 appear in the page footer.SummaryDifference0.1%

- Check44 days agoChange DetectedAdded Kansas under Locations and updated page revision to v3.3.3; removed HHS Vulnerability Disclosure and Kansas Locations.SummaryDifference0.2%

- Check66 days agoChange DetectedThe page shows a minor revision label (Revision: v3.3.2) replacing v3.3.1; no observed changes to core content, eligibility, outcomes, or trial details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check73 days agoChange DetectedPublications section updated to note that entries are automatically filled from PubMed and may not be about the study, and the revision tag updated to v3.3.1. The previous wording stating PubMed-derived articles were automatically created by ClinicalTrials.gov Identifier was removed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Periop mFOLFOX + Pembrolizumab in GEJ & Stomach Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Periop mFOLFOX + Pembrolizumab in GEJ & Stomach Clinical Trial page.